Background Background In the past10 years the
In the past10 years the new atypical antipsychotic drugs have new atypical antipsychotic drugs have stimulated further interest in the stimulated further interest in the pharmacological management of pharmacological management of schizophrenia.The risk of movement schizophrenia.The risk of movement disorders has been reported to be less disorders has been reported to be less with these new agents. with these new agents.
Aims Aims To examine the current
To examine the current prevalence of movement disorders among prevalence of movement disorders among all people with schizophrenia in a discrete all people with schizophrenia in a discrete geographical area, to compare the geographical area, to compare the prevalence in patients receiving and not prevalence in patients receiving and not receiving atypical antipsychotic drugs; and receiving atypical antipsychotic drugs; and to compare current prevalence with to compare current prevalence with prevalence over the past 20 years. prevalence over the past 20 years.
Method Method In Nithsdale, south-west
In Nithsdale, south-west Scotland, in1999/2000, we replicated Scotland, in1999/2000, we replicated previous studies by using the Abnormal previous studies by using the Abnormal Involuntary Movements Scale, SimpsonÎnvoluntary Movements Scale, SimpsonÂ ngus scale and Barnes Akathisia Rating Angus scale and Barnes Akathisia Rating Scale to measure tardive dyskinesia, Scale to measure tardive dyskinesia, parkinsonism and akathisia, respectively. parkinsonism and akathisia, respectively. Mental state was assessed by the Positive Mental state was assessed by the Positive and Negative Syndrome Scale. and Negative Syndrome Scale.
Results

Results In136 patients the prevalence
In136 patients the prevalence of probable tardive dyskinesia was 43%, of of probable tardive dyskinesia was 43%, of parkinsonism 35% and of akathisia15%. parkinsonism 35% and of akathisia15%. Parkinsonism was present as often in those Parkinsonism was present as often in those receiving atypicals as in those receiving receiving atypicals as in those receiving standard oral antipsychotics.The standard oral antipsychotics.The prevalence of tardive dyskinesia has prevalence of tardive dyskinesia has doubled over 20 years. doubled over 20 years.
Conclusions Conclusions Movement disorders
Movement disorders remain significant problems for patients remain significant problems for patients despite the introduction of atypical despite the introduction of atypical antipsychotic drugs. antipsychotic drugs.
Declaration of interest Declaration of interest None.
None.
Over the past two decades there have been Over the past two decades there have been major changes in the management of major changes in the management of people with schizophrenia, with a move people with schizophrenia, with a move towards community care. Recently, this towards community care. Recently, this has been associated with the use of atypical has been associated with the use of atypical antipsychotic drugs, which produce fewer antipsychotic drugs, which produce fewer extrapyramidal side-effects (Geddes extrapyramidal side-effects (Geddes et al et al, , 2000) . Such side-effects are distressing, dis-2000) . Such side-effects are distressing, disfiguring and contribute to the stigma of figuring and contribute to the stigma of mental illness. In Nithsdale, in Dumfries mental illness. In Nithsdale, in Dumfries and Galloway, south-west Scotland, we and Galloway, south-west Scotland, we have studied the prevalence of movement have studied the prevalence of movement disorders since 1981 (McCreadie disorders since 1981 (McCreadie et al et al, , 1982) . We report here our most recent 1982). We report here our most recent findings on: current prevalence (1999/ findings on: current prevalence (1999/ 2000) ; an examination of factors possibly 2000); an examination of factors possibly associated with extrapyramidal disorders associated with extrapyramidal disorders such as medication and smoking; a comparsuch as medication and smoking; a comparison with prevalence assessed on six preison with prevalence assessed on six previous occasions (McCreadie vious occasions (McCreadie et al et al, 1982 (McCreadie et al et al, , , 1982 (McCreadie et al et al, , 1992 Kelly 1992; Kelly et al et al, 1998) ; and a longitudinal , 1998); and a longitudinal study of patients assessed in both 1981 and study of patients assessed in both 1981 and 2000. We hypothesised that the prevalence 2000. We hypothesised that the prevalence of movement disorders would be lower of movement disorders would be lower than in previous years, and that their than in previous years, and that their prevalence would be lower in patients prevalence would be lower in patients receiving atypical antipsychotics than in receiving atypical antipsychotics than in those receiving standard antipsychotics. those receiving standard antipsychotics.
METHOD METHOD Setting Setting
Nithsdale is a well-defined area in the Nithsdale is a well-defined area in the Dumfries and Galloway region of southDumfries and Galloway region of southwest Scotland, UK. It has a population of west Scotland, UK. It has a population of about 57 000. All in-patient services are about 57 000. All in-patient services are provided at Crichton Royal Hospital in provided at Crichton Royal Hospital in Dumfries and out-patient care is provided Dumfries and out-patient care is provided by community mental health teams. by community mental health teams.
Patient identification Patient identification
The identification of patients by the 'key The identification of patients by the 'key informant' method has been described informant' method has been described previously (McCreadie, 1982; Kelly previously (McCreadie, 1982; Kelly et al et al, , 1998) . There are regular censuses of people 1998). There are regular censuses of people with schizophrenia in Nithsdale; patients in with schizophrenia in Nithsdale; patients in the present study were identified in April the present study were identified in April 1999 and examined over the following 12 1999 and examined over the following 12 months. The census includes all in-patients, months. The census includes all in-patients, day patients and out-patients on the census day patients and out-patients on the census date with an address in Nithsdale and an date with an address in Nithsdale and an ICD-10 (World Health Organization, ICD-10 (World Health Organization, 1992) McGuffin et al et al, 1991) with a , 1991) with a computer-generated ICD-10 diagnosis computer-generated ICD-10 diagnosis were generated by J.H. were generated by J.H.
Assessment Assessment
Socio-demographic data were obtained Socio-demographic data were obtained from both case records and interviews. from both case records and interviews. We recorded age, gender, duration of illWe recorded age, gender, duration of illness (as estimated from the time of the first ness (as estimated from the time of the first psychotic episode) and medication both at psychotic episode) and medication both at the time of interview and over the precedthe time of interview and over the preceding year. Dyskinesia was assessed by four ing year. Dyskinesia was assessed by four psychiatrists (J.H., S.M., T.M., R.M.) using psychiatrists (J.H., S.M., T.M., R.M.) using the Abnormal Involuntary Movements the Abnormal Involuntary Movements Scale (AIMS; US Department of Health, Scale (AIMS; US Department of Health, Education and Welfare, 1976) . Dyskinesia Education and Welfare, 1976) . Dyskinesia was defined as probably present (Schooler was defined as probably present (Schooler & Kane, 1982) if movements were 'mild ' & Kane, 1982) if movements were 'mild' in at least two of seven body areas or in at least two of seven body areas or 'moderate' in at least one. Parkinsonism 'moderate' in at least one. Parkinsonism was assessed using the Simpson-Angus was assessed using the Simpson-Angus Rating Scale (Simpson & Angus, 1970) Rating Scale (Simpson & Angus, 1970) and was said to be present if the score and was said to be present if the score was more than 0.3. was more than 0.3. Akathisia was measured using the Akathisia was measured using the Barnes Akathisia Rating Scale (BARS) and Barnes Akathisia Rating Scale (BARS) and was said to be present if the score was 2 was said to be present if the score was 2 ('mild') or more on the global scale (Barnes, ('mild') or more on the global scale (Barnes, 1989 (Barnes, ). 1989 .
Mental state was assessed by the same Mental state was assessed by the same psychiatrists using the Positive and Negapsychiatrists using the Positive and Negative Syndrome Scale (PANSS) for schizotive Syndrome Scale (PANSS) for schizophrenia (Kay phrenia (Kay et al et al, 1987) ; this gives a , 1987); this gives a total score and also scores on positive, total score and also scores on positive, negative and general psychopathology negative and general psychopathology sub-scales. sub-scales.
Patients completed a questionnaire Patients completed a questionnaire about their smoking habits, as in a health about their smoking habits, as in a health and lifestyle survey of the general popuand lifestyle survey of the general population in south-west Scotland (Waldron lation in south-west Scotland (Waldron et al et al, 1995) .
, 1995). Training and practice sessions in the Training and practice sessions in the assessment of mental state and movement assessment of mental state and movement disorders took place before the study began disorders took place before the study began under the supervision of R.M. under the supervision of R.M.
Statistical analysis Statistical analysis
Differences in proportions were measured Differences in proportions were measured using the chi-squared test, with Yate's using the chi-squared test, with Yate's correction for 2 correction for 26 62 tables. Normally distri-2 tables. Normally distributed data were presented with means and buted data were presented with means and standard deviations, and standard deviations, and t t-tests were used -tests were used to measure significance: tests were twoto measure significance: tests were twotailed. As there were many comparisons, tailed. As there were many comparisons, only differences significant at least at the only differences significant at least at the 1% level are reported. In order to account 1% level are reported. In order to account for the possible correlations between for the possible correlations between variables, logistic regression was used to variables, logistic regression was used to identify variables independently associated identify variables independently associated with tardive dyskinesia. All statistical with tardive dyskinesia. All statistical analyses were performed using Arcus analyses were performed using Arcus Quickstat Biochemical (Biomedical version Quickstat Biochemical (Biomedical version 1.2; Longman Software, 1999 (Table 1 ). There were akathisia in 15% (Table 1 ). There were no significant gender differences in the no significant gender differences in the prevalence of the three movement disprevalence of the three movement disorders. The patients who did not take part orders. The patients who did not take part in the study did not differ from those who in the study did not differ from those who did in age, gender distribution or duration did in age, gender distribution or duration of illness. of illness.
Factors associated with Factors associated with extrapyramidal disorders extrapyramidal disorders
In males there were no significant differIn males there were no significant differences between those with and without ences between those with and without tardive dyskinesia in age, mental state tardive dyskinesia in age, mental state and smoking status. Male patients with and smoking status. Male patients with tardive dyskinesia had a significantly tardive dyskinesia had a significantly longer duration of illness (Table 2) . No longer duration of illness (Table 2) . No other significant differences in males were other significant differences in males were found. found.
In females, patients with tardive dysIn females, patients with tardive dyskinesia had significantly higher negative kinesia had significantly higher negative symptom, general psychopathology and symptom, general psychopathology and total scores on the PANSS (Table 2) . total scores on the PANSS (Table 2) . Similar significant differences in PANSS Similar significant differences in PANSS scores were found between females with scores were found between females with and without parkinsonism (negative and without parkinsonism ( ¼6.8, 6.8, P P¼0.009). 0.009).
The variables that were significantly The variables that were significantly different in female patients with and different in female patients with and without tardive dyskinesia on univariate without tardive dyskinesia on univariate analysis were re-examined using logistic analysis were re-examined using logistic regression. Negative symptoms and akathisia regression. Negative symptoms and akathisia remained independently significantly remained independently significantly associated with those females who had associated with those females who had tardive dyskinesia ( tardive dyskinesia (P P¼0.01, 0.01, P P¼0.007, 0.007, respectively). respectively).
Medication Medication
Patients receiving antipsychotic medication Patients receiving antipsychotic medication were grouped into three categories: those were grouped into three categories: those receiving long-acting intramuscular antireceiving long-acting intramuscular antipsychotic drugs with or without other antipsychotic drugs with or without other antipsychotics; those receiving standard oral psychotics; those receiving standard oral antipsychotic drugs, including sulpiride antipsychotic drugs, including sulpiride and thioridazine, with or without oral and thioridazine, with or without oral atypicals; and those receiving atypical oral atypicals; and those receiving atypical oral antipsychotic drugs alone (Table 3 ). In antipsychotic drugs alone (Table 3) . In males and females separately, and in the males and females separately, and in the total group, there were no significant differtotal group, there were no significant differences between any of the medication cateences between any of the medication categories in the number of patients with and gories in the number of patients with and without tardive dyskinesia, either over the without tardive dyskinesia, either over the past year or at the time of interview (Table past year or at the time of interview (Table  3) . At the time of interview, 52% of 3). At the time of interview, 52% of patients receiving only atypicals had tardive patients receiving only atypicals had tardive dyskinesia. dyskinesia.
The drugs and their doses are recorded The drugs and their doses are recorded in Table 4 . Numbers of patients receiving in Table 4 . Numbers of patients receiving individual antipsychotic drugs were small individual antipsychotic drugs were small and there were no statistically significant and there were no statistically significant differences in the doses of the various drugs differences in the doses of the various drugs in those who did and did 4 2 3 4 2 3 (5) 14 (6) 14 (6) 15 (6) 15 (6) 13 (7) 13 (7) 14 (5) 14 (5) 14 (6) 14 (6) P-Neg, mean (s.d.) P-Neg, mean (s.d.) 17 (5) 17 (5) 19 (7) 19 (7) 19 (9) 19 (9) 12 (5)** 12 (5)** 18 (7) 18 (7) 15 (7) 15 (7) P-Gen, mean (s. (88) 30 (88) 23 (66) 23 (66) 11 (46) 11 (46) 20 (52) 20 (52) 41 (71) 41 (71) 43 (55) 43 (55) P-Pos, score on positive symptom subscale of PANSS; P-Neg, score on negative symptom subscale of PANSS; P-Gen, score on general psychopathology subscale of PANSS; P-Total, P-Pos, score on positive symptom subscale of PANSS; P-Neg, score on negative symptom subscale of PANSS; P-Gen, score on general psychopathology subscale of PANSS; P-Total, total score on PANSS. total score on PANSS. We examined more closely the patients We examined more closely the patients who were receiving atypicals alone ( who were receiving atypicals alone (n n¼48). 48). The mean length of time for which the 25 The mean length of time for which the 25 who had tardive dyskinesia had been who had tardive dyskinesia had been receiving their current drug was 31 months receiving their current drug was 31 months (s.d. (s.d.¼26). The reasons for that drug being 26). The reasons for that drug being started were: fresh episode or worsening started were: fresh episode or worsening of psychotic symptoms ( of psychotic symptoms (n n¼16, 64%); 16, 64%); unacceptable extrapyramidal side-effects unacceptable extrapyramidal side-effects ( (n n¼3, 12%); other side-effects ( 3, 12%); other side-effects (n n¼4, 4, 16%); not known ( 16%); not known (n n¼2, 8%). Of the 23 2, 8%). Of the 23 without tardive dyskinesia, the mean length without tardive dyskinesia, the mean length of time on the current drug was not signifiof time on the current drug was not significantly different (mean 23 months, s.d. cantly different (mean 23 months, s.d.¼19). 19). The reasons for starting were: fresh episode The reasons for starting were: fresh episode or worsening of psychotic symptoms or worsening of psychotic symptoms ( (n n¼13, 57%); unacceptable extrapyramidal 13, 57%); unacceptable extrapyramidal side-effects ( side-effects (n n¼1, 4%); other side-effects 1, 4%); other side-effects ( (n n¼5, 22%); not known ( 5, 22%); not known (n n¼4, 17%). 4, 17%). Medication status was also examined in Medication status was also examined in patients with parkinsonism and akathisia patients with parkinsonism and akathisia over the past year and at the time of interover the past year and at the time of interview. When males and females were view. When males and females were considered separately, no significant difconsidered separately, no significant differences between the groups were found. ferences between the groups were found. However, in the total group parkinsonism However, in the total group parkinsonism was significantly more common in patients was significantly more common in patients receiving long-acting intramuscular antireceiving long-acting intramuscular antipsychotic medication (Table 5 ). Of those psychotic medication (Table 5 ). Of those receiving atypicals alone, 29% had parkinreceiving atypicals alone, 29% had parkinsonism and 18% had akathisia. sonism and 18% had akathisia.
With regard to parkinsonism, we With regard to parkinsonism, we examined more closely those patients reexamined more closely those patients receiving only standard oral antipsychotic ceiving only standard oral antipsychotic medication ( medication (n n¼34). Of the 25 patients 34). Of the 25 patients who were receiving sulpiride or thioriwho were receiving sulpiride or thioridazine, 6 (24%) had parkinsonism. Of the dazine, 6 (24%) had parkinsonism. Of the 9 on the other standard antipsychotic medi-9 on the other standard antipsychotic medication (e.g. trifluoperazine) 6 (67%) had cation (e.g. trifluoperazine) 6 (67%) had parkinsonism. parkinsonism.
In a further comparison of patients with In a further comparison of patients with and without movement disorders, there and without movement disorders, there were no significant differences in the were no significant differences in the numbers of patients receiving either antinumbers of patients receiving either antidepressant or antiparkinsonian medication depressant or antiparkinsonian medication at the time of interview or over the previous at the time of interview or over the previous year. year.
Comparison with previous reviews Comparison with previous reviews
The prevalence of tardive dyskinesia has The prevalence of tardive dyskinesia has been assessed in Nithsdale using the AIMS been assessed in Nithsdale using the AIMS scale on seven occasions, including 1999/ scale on seven occasions, including 1999/ 2000, since 1981 (Table 6 ). For each assess-2000, since 1981 (Table 6 ). For each assessment, all known patients with schizoment, all known patients with schizophrenia are identified. Each cohort phrenia are identified. Each cohort contains patients from the previous cohort, contains patients from the previous cohort, still alive and living in Nithsdale, and also still alive and living in Nithsdale, and also new patients who have developed the illnew patients who have developed the illness for the first time or who have moved ness for the first time or who have moved to the area; some from the previous cohort to the area; some from the previous cohort will have moved away or died. Thus, the will have moved away or died. Thus, the mean age of the patients over the years mean age of the patients over the years remains very similar (Table 6 ). The preremains very similar (Table 6 ). The prevalence of tardive dyskinesia has more than valence of tardive dyskinesia has more than doubled over 20 years ( doubled over 20 years (w w 2 2 for linear for linear trend trend¼16.89, 16.89, P P5 50.0001). The prevalence 0.0001). The prevalence of parkinsonism and akathisia, assessed less of parkinsonism and akathisia, assessed less often, has remained broadly the same often, has remained broadly the same (Table 6 ). (Table 6) . A standard oral also was received by 7 patients, an atypical also by 1 patient. 1. A standard oral also was received by 7 patients, an atypical also by 1 patient. 2. More than 1 oral standard was received by 2 patients, 14 patients also received atypicals. 2. More than 1 oral standard was received by 2 patients, 14 patients also received atypicals. 3. Data on dosing was missing for 1 patient with tardive dyskinesia on olanzapine who was therefore not included. 3. Data on dosing was missing for 1 patient with tardive dyskinesia on olanzapine who was therefore not included. 4. Daily dose for oral drugs, weekly dose for long-acting intramuscular drugs. 4. Daily dose for oral drugs, weekly dose for long-acting intramuscular drugs. (29) 14 (29) 13 (27) 13 (27) Total, Total, n n (%)
With TD With TD 12 (48) 12 (48) 18 (38) 18 (38) 25 (52) 25 (52) Without TD Without TD 13 (52) 13 (52) 30 (62) 30 (62) 23 (48) 23 (48) patients, respectively); flupentixol decanopatients, respectively); flupentixol decanoate (29 and 9 patients, respectively); and ate (29 and 9 patients, respectively); and fluphenazine decanoate (27 and 5 patients, fluphenazine decanoate (27 and 5 patients, respectively). For the patients receiving respectively). For the patients receiving thioridazine, the mean dose was signithioridazine, the mean dose was signi- Nithsdale in 1999/2000, and were reexamined. Of the 34, 23 had been rated on examined. Of the 34, 23 had been rated on 7 occasions, 9 on 6 occasions, 1 on 5 7 occasions, 9 on 6 occasions, 1 on 5 occasions and 1 on 4 occasions. Seven occasions and 1 on 4 occasions. Seven patients (21%) had never shown tardive patients (21%) had never shown tardive dyskinesia dyskinesia compared with 27 (79%) who compared with 27 (79%) who had tardive dyskinesia on at least one had tardive dyskinesia on at least one occasion. Of those who had tardive dysoccasion. Of those who had tardive dyskinesia on at least one occasion, 7 (26%) kinesia on at least one occasion, 7 (26%) developed the persistent condition (positive developed the persistent condition (positive rating on the last three assessments); the rating on the last three assessments); the remaining 20 (74%) had no clear pattern. remaining 20 (74%) had no clear pattern.
No patient had persistent tardive dyskinesia No patient had persistent tardive dyskinesia (positive on three consecutive occasions) (positive on three consecutive occasions) which remitted. which remitted.
DISCUSSION DISCUSSION
Methodological strengths Methodological strengths and weaknesses and weaknesses
Of the total number of patients identified Of the total number of patients identified by the key informant method, 76% took by the key informant method, 76% took part in the study. Those who did not take part in the study. Those who did not take part did not differ in age, gender distripart did not differ in age, gender distribution or duration of illness from those bution or duration of illness from those who did. Although not all assessments were who did. Although not all assessments were carried out by the same psychiatrist, tardive carried out by the same psychiatrist, tardive dyskinesia was rated on each occasion over dyskinesia was rated on each occasion over the 20 years using the same scale (AIMS) the 20 years using the same scale (AIMS) and one of us (R.M.) was involved in every and one of us (R.M.) was involved in every study and was responsible for training. study and was responsible for training.
Tardive dyskinesia Tardive dyskinesia
We found the prevalence of probable tarWe found the prevalence of probable tardive dyskinesia to be 43%. This is in keeping dive dyskinesia to be 43%. This is in keeping with a review (Casey, 1995) that reported with a review (Casey, 1995) that reported mild forms of the condition in approximild forms of the condition in approximately 20% of patients, rising to 50% in mately 20% of patients, rising to 50% in high-risk groups such as the elderly. Several high-risk groups such as the elderly. Several risk factors for tardive dyskinesia have been risk factors for tardive dyskinesia have been identified, such as advanced age and duraidentified, such as advanced age and duration of illness (McCreadie, 1982 ; Kane tion of illness (McCreadie, 1982; Kane et al et al, 1992) . Conflicting results have been , 1992). Conflicting results have been found with gender (Yassa & Jeste, 1992) found with gender (Yassa & Jeste, 1992) and smoking (Kelly & McCreadie, 1999) . and smoking (Kelly & McCreadie, 1999) . The only risk factor in our study signifiThe only risk factor in our study significantly associated with tardive dyskinesia cantly associated with tardive dyskinesia was longer duration of illness in male was longer duration of illness in male patients. The association of tardive dyspatients. The association of tardive dyskinesia with negative symptoms has been kinesia with negative symptoms has been reported elsewhere (Liddle reported elsewhere (Liddle et al et al, 1993) . In , 1993). In our study, female patients with tardive dysour study, female patients with tardive dyskinesia were likely to have more negative kinesia were likely to have more negative symptoms and general psychopathology. symptoms and general psychopathology. The finding with regard to negative The finding with regard to negative symptoms remained independently signisymptoms remained independently significant on logistic regression. In females, ficant on logistic regression. In females, parkinsonism and akathisia were associated parkinsonism and akathisia were associated with tardive dyskinesia, but following with tardive dyskinesia, but following logistic regression only akathisia remained logistic regression only akathisia remained independently significantly associated. We independently significantly associated. We can only speculate why akathisia is assocan only speculate why akathisia is associated with tardive dyskinesia in females ciated with tardive dyskinesia in females but not in males. The influence of oestrogen but not in males. The influence of oestrogen on movement disorders is complex. It has on movement disorders is complex. It has been suggested that females experience a been suggested that females experience a higher frequency of akathisia, possibly higher frequency of akathisia, possibly because of the additive effects of oestrogen because of the additive effects of oestrogen and antipsychotics on dopamine blockade. and antipsychotics on dopamine blockade. Also, oestrogen decline in postmenopausal Also, oestrogen decline in postmenopausal women may precipitate tardive dyskinesia women may precipitate tardive dyskinesia by relieving dopamine blockade, as may by relieving dopamine blockade, as may withdrawal of antipsychotic medication withdrawal of antipsychotic medication (Leung & Chue, 2000) . So, the presence (Leung & Chue, 2000) . So, the presence of oestrogen in the young and lack of it in of oestrogen in the young and lack of it in the old may be responsible for the assothe old may be responsible for the association of akathisia with tardive dyskinesia ciation of akathisia with tardive dyskinesia in women. in women.
Parkinsonism and akathisia Parkinsonism and akathisia
Drug-induced parkinsonism occurs Drug-induced parkinsonism occurs especially during the initial period of antiespecially during the initial period of antipsychotic medication exposure (Casey, psychotic medication exposure (Casey, 1995) . Prevalence rates of 20% (Modestin 1995) . Prevalence rates of 20% (Modestin et al et al, 2000) and 36% (van Harten , 2000) and 36% (van Harten et al et al, , 1996) have been reported. This range is 1996) have been reported. This range is in keeping with our study, where the in keeping with our study, where the prevalence was 35%. prevalence was 35%.
The prevalence of akathisia, one of the The prevalence of akathisia, one of the most intolerable extrapyramidal side-effects most intolerable extrapyramidal side-effects which often leads to non-compliance, has which often leads to non-compliance, has 4 2 5 4 2 5 (38) 18 (38) 16 (33) 16 (33) Total, Total, n n (%) (%) 1 1 With parkinsonism With parkinsonism 15 (60) 15 (60) 13 (27) 13 (27) 14 (29) 14 (29) Without parkinsonism Without parkinsonism 10 (40) 10 (40) 35 (73) 35 (73) 34 (71) 34 (71) been reported as 11% (Modestin been reported as 11% (Modestin et al et al, , 2000) , much the same as our finding of 2000), much the same as our finding of 15%. 15%.
Medication Medication
There was no difference in the prevalence of There was no difference in the prevalence of tardive dyskinesia in the three medication tardive dyskinesia in the three medication categories; the condition was present in categories; the condition was present in 52% of patients currently receiving 52% of patients currently receiving atypicals only. There are several possible atypicals only. There are several possible reasons for the findings in the present study. reasons for the findings in the present study. Tardive dyskinesia secondary to standard Tardive dyskinesia secondary to standard antipsychotics may persist even when such antipsychotics may persist even when such drugs are discontinued; the patients with drugs are discontinued; the patients with tardive dyskinesia may have been preferenttardive dyskinesia may have been preferentially switched to atypicals; withdrawal dysially switched to atypicals; withdrawal dyskinesia may develop after discontinuation kinesia may develop after discontinuation of standard antipsychotics; and some of standard antipsychotics; and some patients have spontaneous rather than patients have spontaneous rather than tardive dyskinesia. With regard to the tardive dyskinesia. With regard to the preferential switch to atypicals, tardive preferential switch to atypicals, tardive dyskinesia was the reason for the change dyskinesia was the reason for the change in only 8% of the 48 patients receiving in only 8% of the 48 patients receiving atypicals. atypicals.
We must emphasise that our study is We must emphasise that our study is one of prevalence, not incidence. The only one of prevalence, not incidence. The only satisfactory way to assess the incidence of satisfactory way to assess the incidence of tardive dyskinesia produced by different tardive dyskinesia produced by different drugs is to follow prospectively patients drugs is to follow prospectively patients suffering their first episode of illness and suffering their first episode of illness and treated with a single drug. treated with a single drug.
A recent review has shown that extra-A recent review has shown that extrapyramidal symptoms, including parkinpyramidal symptoms, including parkinsonism, are less common with atypical sonism, are less common with atypical antipsychotic medication than with antipsychotic medication than with standard antipsychotics (Geddes standard antipsychotics (Geddes et al et al, , 2000) . In our study, parkinsonism was 2000). In our study, parkinsonism was certainly less common than in those certainly less common than in those receiving long-acting intramuscular antireceiving long-acting intramuscular antipsychotics; yet the prevalence in those psychotics; yet the prevalence in those receiving atypicals was 29%. This is not receiving atypicals was 29%. This is not because patients had recently been switched because patients had recently been switched to atypicals and were still experiencing conto atypicals and were still experiencing continuing side-effects produced by standard tinuing side-effects produced by standard antipsychotics: the mean length of time antipsychotics: the mean length of time patients had been receiving atypicals was patients had been receiving atypicals was 27 months. The prevalence of parkinsonism 27 months. The prevalence of parkinsonism was similar in those receiving oral stanwas similar in those receiving oral standards (27%) and atypicals (29%). Howdards (27%) and atypicals (29%). However, 74% of patients on oral standards ever, 74% of patients on oral standards were receiving either thioridazine or were receiving either thioridazine or sulpiride, two drugs which may be 'older sulpiride, two drugs which may be 'older atypicals'; Baldessarini (1980) wrote atypicals'; Baldessarini (1980) wrote more than 20 years ago that sulpiride and more than 20 years ago that sulpiride and thioridazine 'are at least partial exceptions thioridazine 'are at least partial exceptions to the formerly almost inevitable associato the formerly almost inevitable association of neurotoxic with antipsychotic tion of neurotoxic with antipsychotic effects'. effects'.
Movement disorders across Movement disorders across 20 years 20 years
The prevalence of tardive dyskinesia has The prevalence of tardive dyskinesia has doubled over the past 20 years. There are doubled over the past 20 years. There are several possible reasons: more patients several possible reasons: more patients may be receiving medication; doses may may be receiving medication; doses may be higher; early intervention may mean be higher; early intervention may mean patients are starting medication at an patients are starting medication at an earlier age and have been taking drugs earlier age and have been taking drugs longer; and, because more patients are in longer; and, because more patients are in the community, drug holidays are more the community, drug holidays are more likely (van Harten likely (van Harten et al et al, 1998) . With regard , 1998). With regard to the first possibility, more patients indeed to the first possibility, more patients indeed were receiving medication in 1999/2000 were receiving medication in 1999/2000 than in 1981. This is probably the result than in 1981. This is probably the result of more assertive community outreach. of more assertive community outreach. With regard to the second possibility, only With regard to the second possibility, only four drugs were prescribed to substantial four drugs were prescribed to substantial numbers of patients in both 1981 and numbers of patients in both 1981 and 1999/2000; the mean dose of one of them, 1999/2000; the mean dose of one of them, thioridazine, was in fact lower in 1999/ thioridazine, was in fact lower in 1999/ 2000. 2000.
Of the 34 patients followed for 20 Of the 34 patients followed for 20 years, 79% had tardive dyskinesia on at years, 79% had tardive dyskinesia on at least one occasion. This suggests that in least one occasion. This suggests that in almost all patients with chronic illness, dysalmost all patients with chronic illness, dyskinesia is an inevitable occurrence. We can kinesia is an inevitable occurrence. We can only speculate how much of this dyskinesia only speculate how much of this dyskinesia is drug-related and how much spontaneous. is drug-related and how much spontaneous. A recent review (Fenton, 2000) has sug-A recent review (Fenton, 2000) has suggested that 40% of those aged 60 years or gested that 40% of those aged 60 years or over have spontaneous dyskinesia. over have spontaneous dyskinesia.
Although numbers are small, our results Although numbers are small, our results suggest there may be two types of dyssuggest there may be two types of dyskinesia: a milder form which fluctuates kinesia: a milder form which fluctuates over time (the majority) and a more severe over time (the majority) and a more severe form which persists once it develops (the form which persists once it develops (the minority). It has long been known that minority). It has long been known that milder forms of tardive dyskinesia may milder forms of tardive dyskinesia may show temporal fluctuations (Bergen show temporal fluctuations (Bergen et al et al, , 1989 (Bergen et al et al, , ). 1989 .
Although the number of assessments Although the number of assessments were fewer, our results suggest that the prewere fewer, our results suggest that the prevalences of parkinsonism and akathisia valences of parkinsonism and akathisia have changed little. If some of the reasoning have changed little. If some of the reasoning as to why tardive dyskinesia is increasing is as to why tardive dyskinesia is increasing is correct, then it might be expected that the correct, then it might be expected that the prevalence of parkinsonism would also rise. prevalence of parkinsonism would also rise. However, the switch from long-acting However, the switch from long-acting intramuscular antipsychotics and 'old' intramuscular antipsychotics and 'old' standards to atypicals may be having a standards to atypicals may be having a protective effect. protective effect.
We conclude that tardive dyskinesia We conclude that tardive dyskinesia and parkinsonism remain major problems and parkinsonism remain major problems despite the introduction of atypical despite the introduction of atypical antipsychotic medication 10 years ago. antipsychotic medication 10 years ago. Further prospective studies are required to Further prospective studies are required to determine whether or not the use of atypidetermine whether or not the use of atypicals will impact on the prevalences of these cals will impact on the prevalences of these movement disorders. movement disorders.
